"Mount Sinai Study Identifies Potential New Treatment Target For Aggressive Bladder Cancer"
A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report. The cancer, called p53-like bladder cancer, is named after an active gene signature it is associated with. The Mount Sinai study, published in July 2018 in Oncogene, describes how researchers applied a computational method they had previously developed, called ActMiR, to bladder cancer genomic data in The Cancer Genomic Atlas to identify two novel biomarkers in p53-like bladder cancers that could accurately predict patient outcomes. "p53-like bladder cancers are generally resistant to standard chemotherapy treatment, and prognoses for these patients are so varied,” said Jun Zhu, PhD, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and head of data science at Sema4. "Our computational methods not only provided us with deeper insights into the cellular mechanisms underlying this elusive type of bladder cancer, but also reveal the potential of microRNAs as therapeutic targets in treating it.”
- Eunjee Lee, PhD, Senior Scientists, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, Director, Integrative Networks, Sema4
- Jun Zhu, PhD, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, Head, Data Science, Sema4
- Matthew Galsky, MD, Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai
- Adam Margolin, PhD, Senior Associate Dean, Precision Medicine, Icahn School of Medicine at Mount Sinai
Additional coverage:
Health Imaging
Fierce Biotech